These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 13295486)

  • 1. Quantitative studies on the properdin-complement system.
    LEON MA
    J Exp Med; 1956 Mar; 103(3):285-93. PubMed ID: 13295486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative studies on the properdin-complement system. II. Kinetics of the reaction between properdin and zymosan.
    LEON MA
    J Exp Med; 1957 May; 105(5):403-15. PubMed ID: 13428911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative studies of the properdin-complement system. III. Kinetics of the reaction between C'3 and the properdin-zymosan complex.
    LEON MA
    J Immunol; 1958 Jul; 81(1):23-8. PubMed ID: 13563875
    [No Abstract]   [Full Text] [Related]  

  • 4. Breakdown products of C 3 in human synovial fluids.
    Zvaifler NJ
    J Clin Invest; 1969 Aug; 48(8):1532-42. PubMed ID: 4183680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The properdin system and immunity. III. The zymosan assay of properdin.
    PILLEMER L; BLUM L; LEPOW IH; WURZ L; TODD EW
    J Exp Med; 1956 Jan; 103(1):1-13. PubMed ID: 13278451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The properdin system and immunity. VI. The inactivation of Newcastle disease virus by the properdin system.
    GINSBERG HS; PILLEMER L; WEDGWOOD RJ
    J Exp Med; 1956 Nov; 104(5):707-25. PubMed ID: 13367339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The possible role of the properdin system in transplantable cancer; the effect of zymosan on transplantable human carcinoma.
    HERBUT PA; KRAEMER WH
    Cancer Res; 1956 Dec; 16(11):1048-52. PubMed ID: 13383472
    [No Abstract]   [Full Text] [Related]  

  • 8. The properdin system and immunity. VII. Alterations in properdin levels and resistance to infection in mice following the administration of tissue polysaccharides.
    PILLEMER L; LANDY M; SHEAR MJ
    J Exp Med; 1957 Jul; 106(1):99-110. PubMed ID: 13439118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immuno-electrophoretic studies on properdin-zymosan and properdin-inulin complex; an analysis of electrophoretic and immunologic behavior of properdin].
    SCHEIFFARTH F; FRENGER W; GOTZ H
    Klin Wochenschr; 1958 Apr; 36(8):367-9. PubMed ID: 13550834
    [No Abstract]   [Full Text] [Related]  

  • 10. The properdin system and immunity. V. The bactericidal activity of the properdin system.
    WARDLAW AC; PILLEMER L
    J Exp Med; 1956 May; 103(5):553-75. PubMed ID: 13319578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [NATURAL INNATE IMMUNITY FOR BRUCELLA MELITENSIS. I. RELATION WITH PROPERDIN, COMPLEMENT, BACTERICIDAL PROPERTIES OF SERUM AND THE FORMATION OF SPECIFIC ANTIBODIES].
    LEON AP; OSOLLO G; CANO C
    Rev Inst Salubr Enferm Trop; 1962 Dec; 22():145-72. PubMed ID: 14076958
    [No Abstract]   [Full Text] [Related]  

  • 12. The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.
    Müllerèberhard HJ; Dalmasso AP; Calcott MA
    J Exp Med; 1966 Jan; 123(1):33-54. PubMed ID: 4159289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methodical and clinical research on the properdin system. II. Research on the behavior of the serum properdin and the C'3 components after gynecological operations].
    SCHUMACHER G; EL HABASH E; SCHLUMBERGER HD
    Arch Gynakol; 1961; 196():167-79. PubMed ID: 13748953
    [No Abstract]   [Full Text] [Related]  

  • 14. Elevation of properdin levels in mice following administration of bacterial lipopolysaccharides.
    LANDY M; PILLEMER L
    J Exp Med; 1956 Jun; 103(6):823-33. PubMed ID: 13319594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVIDENCE FOR IMMUNOLOGICAL SPECIFICITY OF THE PROPERDIN SYSTEM; DEMONSTRATION, ISOLATION AND PROPERTIES OF A SERUM FACTOR WHICH INTERACTS WITH ZYMOSAN AND OTHER POLYSACCHARIDES AT 0 DEGREES CENTIGRADE.
    BLUM L
    J Immunol; 1964 Jan; 92():61-72. PubMed ID: 14139548
    [No Abstract]   [Full Text] [Related]  

  • 16. A NEW METHOD FOR THE STUDY OF CYTOTOXIC SYSTEMS (SPECIFIC EVEN NON-SPECIFIC) OF BLOOD SERUMS.
    RYBAK M; PETAKOVA M; SIMONIANOVA E
    Z Immunitats Allergieforsch; 1963 Oct; 125():351-7. PubMed ID: 14117569
    [No Abstract]   [Full Text] [Related]  

  • 17. Interaction of properdin convertase and properdin in the alternative pathway of complement activation.
    Spitzer RE; Stitzel AE; Urmson J
    Immunochemistry; 1976 Jan; 13(1):15-20. PubMed ID: 943370
    [No Abstract]   [Full Text] [Related]  

  • 18. The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics.
    Brade V; Nicholson A; Lee GD; Mayer MM
    J Immunol; 1974 May; 112(5):1845-54. PubMed ID: 4818461
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
    McLean RH; Townsend K; Michael AF
    Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the immunochemical properties of highly purified properdin in human serum.
    Minta JO
    J Immunol; 1975 Apr; 114(4):1415-21. PubMed ID: 123262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.